<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17983534</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Velasco Calvo, Rocío</dc:author>
<dc:author>Bermejo Velasco, Pedro Emilio</dc:author>
<dc:description xml:lang="en">Neuropathic pain is a phenomenon characterized by a high prevalence in population that may be originated by very different etiologies. In contrast to nociceptive pain, painful signal is originated in the nervous system, it presents poor responses to conventional treatments and may worsen the quality of life. Antiepileptic drugs have demonstrated its effectiveness in the treatment of this pathology, and owing to the important development of these drugs in the last years, they may become a very effective tool. On the other hand, the best knowledge of the physiopathology of nociception is providing new channels and receptors as targets to treat. In this paper we try to review the different potential therapeutical targets and antiepileptic drugs in the treatment of this pathology.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Oct 20 </dc:date>
<dc:title xml:lang="es">Nuevos fármacos antiepilépticos y dolor neuropático. De la medicina molecular a la clínica.</dc:title>
<dc:title xml:lang="en">[New antiepileptic drugs and neuropathic pain. From molecular medicine to clinical practice].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
